|
16 Aug 2022 |
Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older
|
|
13 Aug 2022 |
Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
|
|
09 Aug 2022 |
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
|
|
03 Aug 2022 |
Vaxxinity’s Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates
|
|
28 Jul 2022 |
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
|
|
26 Jul 2022 |
Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include Monkeypox
|
|
26 Jul 2022 |
FDA accepts HOOKIPA’s Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer
|
|
22 Jul 2022 |
Blue Lake Biotechnology Announces First Participant Dosed in a Phase 1 Clinical Trial of Its BLB-201 Intranasal RSV Vaccine
|
|
21 Jul 2022 |
HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate
|
|
20 Jul 2022 |
Immunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma
|
|
14 Jul 2022 |
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over
|
|
06 Jul 2022 |
Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant
|
|
29 Jun 2022 |
Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV
|
|
25 Jun 2022 |
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
|
|
25 Jun 2022 |
Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine
|
|
25 Jun 2022 |
Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001
|
|
24 Jun 2022 |
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
|
|
23 Jun 2022 |
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
|
|
21 Jun 2022 |
Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine
|
|
21 Jun 2022 |
PharmaJet Partner, Nykode Therapeutics, Announces Positive Interim Results in HPV+ Cervical Cancer Phase 2 Trial
|
|
21 Jun 2022 |
Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
|
|
20 Jun 2022 |
Ultimovacs’ UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial
|
|
13 Jun 2022 |
Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
|
|
11 Jun 2022 |
GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults
|
|
06 Jun 2022 |
GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older
|
